Cubist hikes sales 23% on Cubicin growth; Bayer submits new eye drug for Japanese OK;

@FiercePharma: Eli Lilly's 2013 profits forecast surpasses analyst predictions. What gives? More | Follow @FiercePharma

 @AlisonBFierce: What's the buzz? Big Pharma may be on the verge of a buying spree. News | Follow @AlisonBFierce

> Cubist Pharmaceuticals ($CBST) boosted sales in 2012 by 23%, ending the year with $926.4 million in revenue, thanks to double-digit growth in sales of its Cubicin antibiotic. Report

> Bayer submitted its vision treatment VEGF Trap-Eye, sold as Eylea in the U.S., to Japanese regulators for approval in patients with a type of macular edema. Release

> Vivus ($VVUS) shares rose on news that the company shipped almost 13,000 prescriptions for its new weight-loss drug Qsymia for the four weeks ended Dec. 21. Report

> Dr. Reddy's, in the process of buying the Dutch drugmaker OctoPlus, bought up 80% of the company's shares for about 27.4 million euros. Report

> Malaysia is emerging as a major manufacturing hub for Indian pharmaceutical companies eager to expand their businesses in Southeast Asia. Report

> The Pentagon's soaring drug expenses could threaten national security, a report suggests. Report

Medical Device News

 @FierceMedDev: Johnson & Johnson's first vaginal mesh trial revs up this week. More | | Follow @FierceMedDev

@MarkHFierce: Illumina is grabbing Verinata Health for $350M-plus. The buy gets it into fetal Dx business. Story | Follow @MarkHFierce

 @DamianFierce: Unregulated clinical trials are wreaking "havoc" in India, the supreme court says. News | Follow @DamianFierce

> SeraCare refocuses energies on in vitro Dx work. Item

> EndoChoice grabs $45M to back merger with Israeli GI startup. Story

Biotech News

 @FierceBiotech: Indian supreme court: Unregulated trials causing 'havoc'. More | Follow @FierceBiotech

@JohnCFierce: As Big Pharma falters, Big Biotech helps fill a $100B "gap." Editor's Corner | Follow @JohnCFierce

@RyanMFierce: Boehringer doesn't want $LLY's basal insulin analog anymore, amends big diabetes pact. News | Follow @RyanMFierce

> Biotech buyout buzz swells as industry's dealmakers flock to JPMorgan confab. Story

> Gilead and biotech strike antibody deal worth north of $1.1B--maybe. News

> Cubist jumps on to Heptares' growing GPCR bandwagon. Article

Biotech IT News

> Quants collaborate on forecasting value of genomics in medicine. Story

> Is FDA keeping social media from taking flight in pharma? Editor's Corner

> Abbott spinoff AbbVie starts social media effort from scratch. Article

> Agilent unit picks up lab software rights to fuel cancer diagnostics biz. News

CRO News

> WCCT partners with U.S.'s largest trial registry on patient adherence. Article

> Questcor snags CMO BioVectra for $50.7M. News

> Cellular Dynamics signs on with AstraZeneca for drug discovery. Story

> Indian supreme court: Unregulated trials causing 'havoc'. Report

> Clinical Network Services buys CRO Beltas. Item

And Finally... Is the National Center for Drug Free Sport stringent enough to deter athletes from doping? Report (sub. req.)

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.